Bioequivalence and Bioavailability Forum

Hi all,

all those theoretical considerations are of course interesting but are they really practical?

It is exceedingly rare to see a problem arising from average BE due to switching in real life.
Of course several originator companies have jumped on the opportunity to throw dirt at the generics. Think epilepsi medications and what not. So you get a bunch of journals flooded with scaremongering about subjects suffering episodes in situations where they switched from an originator to a generic. But when originators have tried to quantify it with a fair control group, then the evidence disappears completely. And they have tried a lot, believe me.
The variation from an original to a generic is most often not more than from one batch of the originator to the next batch of the same originator.

The problem is twisted information in the public domain and not switching.